Condition Archives - Page 12 of 132

Synergy for Staphylococcus Skin and Skin Structure Infection

Staphylococcus aureus, particularly methicillin-resistant Staphylococcus aureus (MRSA), is a leading cause of skin and skin structure infections (SSSIs), encompassing cellulitis, abscesses, wound infections, and impetigo.…

Condition S

Synergy for Staphylococcal Joint Infection

Staphylococcal joint infections, particularly those caused by Staphylococcus aureus, represent a significant clinical challenge due to their aggressive nature, potential for chronicity, and the emergence…

synergy for skin and skin structure pseudomonas aeruginosa infection

Condition S

Synergistic Strategies for Skin and Skin Structure Infections

Pseudomonas aeruginosa is a gram-negative, opportunistic pathogen known for causing severe skin and skin structure infections (SSSIs), especially in immunocompromised individuals and patients with burns,…

Condition S

Synergy for Serratia Meningitis

Serratia marcescens is a Gram-negative, facultative anaerobic bacillus belonging to the Enterobacteriaceae family. Although more commonly implicated in nosocomial bloodstream infections and urinary tract infections,…

synergy for pseudomonas aeruginosa pneumonia

Condition S

Synergistic Strategies in the Treatment of Pseudomonas aeruginosa

Pseudomonas aeruginosa is a major pathogen in healthcare-associated pneumonia (HCAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its intrinsic resistance mechanisms, adaptive survival strategies, and…

Condition S

Synergy for Pseudomonas aeruginosa Meningitis

Pseudomonas aeruginosa meningitis is a rare but life-threatening infection of the central nervous system (CNS), typically associated with neurosurgical procedures, external ventricular drains (EVD), or…

Condition S

Synergy for Pseudomonas aeruginosa Joint Infection

Pseudomonas aeruginosa is an opportunistic, Gram-negative, non-fermenting bacillus responsible for a subset of joint infections, particularly in immunocompromised individuals, intravenous drug users, or patients with…

synergy for group b streptococcal septicemia

Condition S

Synergistic Antibiotic Strategies in the Treatment of Group B

Group B Streptococcus (GBS), scientifically known as Streptococcus agalactiae, is a Gram-positive bacterium that is a leading cause of septicemia, particularly in neonates and immunocompromised…

Condition S

Synergy for Escherichia coli Meningitis

Escherichia coli (E. coli), a Gram-negative bacillus, is one of the most common etiologic agents of bacterial meningitis, especially in neonates and immunocompromised individuals. Among…

Condition S

Synergy for Enterococcal Infection

Enterococcal infections, primarily caused by Enterococcus faecalis and Enterococcus faecium, represent a significant challenge in clinical settings due to their inherent resistance mechanisms and capacity…